



Development and Challenges of Respiratory Disease Vaccines

Guest Editor:

Prof. Xiaoming Yang

National Engineering Technology
Research Center for Combined
Vaccines, Wuhan, China

Deadline for manuscript
submissions:

closed (31 January 2024)

Message from the Guest Editor

The respiratory system is susceptible to pathogens. Currently, vaccines are available for respiratory diseases such as influenza, COVID-19, pneumonia, pertussis, and tuberculosis (TB). Some infectious respiratory diseases do not yet have a vaccine, such as respiratory syncytial virus (RSV) and the common cold. There are still many troubling issues with existing respiratory vaccines, such as the mutants of influenza virus and SARS-CoV-2; therefore, the development of universal vaccines is now a common concern. As for the RSV vaccine, vaccine-induced pathology is a big safety hurdle.

To achieve a more extensive understanding of recent scientific knowledge and current trends in the development of vaccines that protect against respiratory disease, this Special Issue is focused on the recent scientific and technical progresses made in this field. Based on your extensive knowledge and experience, we invite you to contribute research works which highlight (i) correlates of protection, (ii) the action mechanism of novel vaccine candidates, (iii) vaccine protection and vaccine pathology, and (iv) the development of novel attenuated or universal respiratory disease vaccines.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious
Diseases, College of Veterinary
Medicine, University of Georgia,
Athens, GA 30602-7387, USA

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Author Benefits

Open Access: free for readers, with **article processing charges (APC)** paid by authors or their institutions.

High Visibility: indexed within **Scopus**, **SCIE (Web of Science)**, **PubMed**, **PMC**, **Embase**, **CAPus / SciFinder**, and **other databases**.

Journal Rank: JCR - Q1 (*Immunology*) / CiteScore - Q1 (*Pharmacology (medical)*)

Contact Us

Vaccines Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/vaccines
vaccines@mdpi.com